No Data
Keji Pharmaceutical-B (02171.HK): Submission of a rectification report on FDA findings
Gelonghui, April 29 | Keji Pharmaceutical-B (02171.HK) issued an announcement. The rectification report on the Corrective and Preventive Measures (CAPAs) plan has been submitted to the US Food and Drug Administration (FDA). This submission relates to findings in Form 483 issued by the FDA after an inspection of the clinical production site in Tulham, North Carolina in December 2023. The relevant work is progressing smoothly according to the schedule previously submitted. The company promises to work closely with the FDA to prioritize quality and ensure the production of clinical trial products.
Conoa-B (02162): Phase III clinical trial of spoxibimab injection to treat seasonal allergic rhinitis reached the main end
Conoa-B (02162) issued an announcement. The company is pleased to announce that its Class 1 new drug, CM310, recombinant humanized monogram...
Does This Valuation Of Everest Medicines Limited (HKG:1952) Imply Investors Are Overpaying?
Key Insights The projected fair value for Everest Medicines is HK$20.13 based on 2 Stage Free Cash Flow to Equity Everest Medicines is estimated to be 22% overvalued based on current share price of
Lepu Biopharma Co., Ltd.'s (HKG:2157) 58% Share Price Surge Not Quite Adding Up
Lepu Biopharma Co., Ltd. (HKG:2157) shareholders have had their patience rewarded with a 58% share price jump in the last month. But the gains over the last month weren't enough to make shareholder
On April 26, Heyu-B (02256) spent about HK$472,400 to buy back 149,000 shares
Goodwill B (02256) announced that on April 26, 2024, it cost approximately HK$472,400 to buy back 14.9...
兆科眼科-B:2023 年報